



Participant name:   
Hospital ID:   
CHI/Date of Birth:

**GREAT-2 GRemubamab ErAdication Trial**

Sponsor University of Dundee-NHS Tayside  
Chief Investigator Professor James Chalmers  
IRAS number 1005993

Principal Investigator   
Contact number   
Contact email

**Unscheduled Visit  
to be filed in medical notes as source data**

Date of visit:  Participant trial ID

Please tick to indicate the following has been completed:

Confirmed participant's identity   
Concomitant medications have been reviewed   
Adverse events have been reviewed

Research samples:

Research blood samples   
Sputum sample

Questionnaires:

Quality of Life-Bronchiectasis Questionnaire   
Bronchiectasis Impact Measure Questionnaire

**Physical exam**

Please tick:

Normal   
Abnormal, not clinically significant   
Abnormal clinical significant

If abnormal document abnormality and any actions taken, if any:

Name of doctor making assessment:



Participant name:	
Hospital ID:	
CHI/Date of Birth:	

**Vital signs**

Please enter the results of the following assessments:

Blood pressure		mmHg	Pulse		bpm
Oxygen saturation (room air)		%	Tympanic temperature		°C

The following must be filed in the participant's medical notes:

- Changes to concomitant medications since last visit
- Any adverse events since last visit
- Any other notable findings and actions taken
- If the participant was withdrawn from the trial at this visit, document reason

Any further information of note:

The visit has been carried out as per protocol.

Signature:	
Name:	
Job title:	
Date:	